RENOIR
Pfizer’s Litfulo significantly improved repigmentation in nonsegmental vitiligo
NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment
Pfizer and Valneva’s application for Lyme disease vaccine candidate validated by EMA
There are currently no approved human vaccines for Lyme disease
US FDA accepts supplemental Biologics License Application for Merck’s Enflonsia
The treatment is to protect children under two years of age from respiratory syncytial virus
Pfizer announces phase 3 results for nonsegmental vitiligo treatment
Litfulo delivered significant, clinically meaningful improvements for both face and body
Pfizer’s Talzenna plus Xtandi gets FDA Priority Review for metastatic prostate cancer
The phase 3 trial showed greater than 50% improvement in radiographic progression-free survival
Pfizer announces phase 3 results for potential non-small cell lung cancer treatment
Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and progression-free survival
Pfizer and Innovent Biologics agree on deal worth up to $10.5bn
The companies plan to research and develop 12 new cancer treatments
Study shows infants given RSV vaccination benefit beyond first RSV season
The RSV virus is highly contagious and can cause serious respiratory illness for infants
GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults
RSV affects approximately 64 million people around the world each year
Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer
Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022
Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients
Over 800,000 people worldwide live with haemophilia
Pfizer’s PADCEV gets FDA approval for bladder cancer
Bladder cancer affects more than 614,000 people globally each year